Department of Endocrinology, Bharti Hospital and BRIDE, Karnal, 132001, Haryana, India,
Diabetes Ther. 2014 Jun;5(1):65-72. doi: 10.1007/s13300-014-0067-x. Epub 2014 May 15.
Insulin degludec/insulin aspart (IDegAsp) is the first soluble co-formulation which combines two insulin analogues, and provides effective basal and prandial glycemic coverage. It has been assessed as basal insulin in type 2 diabetes mellitus (T2DM), and as part of basal-bolus regime in both type 1 diabetes mellitus and T2DM. Insulin degludec has also been assessed as flexibly administered basal insulin in terms of time of administration. This review discusses data pertaining to the efficacy, safety, tolerability, and clinical potential of IDegAsp. The discussion includes comparisons of IDegAsp with basal as well as premixed insulin.
德谷胰岛素/门冬胰岛素（IDegAsp）是首个可溶性的双胰岛素复方制剂，它结合了两种胰岛素类似物，可有效控制基础和餐时血糖。该药已被评估为用于 2 型糖尿病（T2DM）的基础胰岛素，也被评估为 1 型糖尿病和 T2DM 的基础-餐时胰岛素方案中的基础胰岛素部分。此外，该药还被评估为可灵活给药的基础胰岛素，给药时间较为灵活。本综述讨论了 IDegAsp 的疗效、安全性、耐受性和临床潜力的数据。讨论内容包括 IDegAsp 与基础胰岛素和预混胰岛素的比较。
